Bethesda IV Follicular Neoplasm is NOT Cancer
A Bethesda IV thyroid nodule is not cancer—it carries a 25-40% risk of malignancy, meaning 60-75% are benign. This is an indeterminate category that requires definitive diagnosis through surgical excision, not a cancer diagnosis itself 1.
Understanding the Risk Stratification
The Bethesda IV category represents a cytological diagnosis of "follicular neoplasm" where fine needle aspiration cannot distinguish between benign follicular adenoma and follicular carcinoma. The actual malignancy risk is 25-40%, which is substantially lower than Bethesda V (50-75%) and Bethesda VI (97-99%) categories 1.
Key Clinical Implications:
Surgery is generally recommended for Bethesda IV nodules because:
- Cytology alone cannot differentiate benign from malignant follicular lesions
- Definitive diagnosis requires histopathological examination of the entire capsule
- Repeat FNAB is usually unnecessary as it won't change the indeterminate nature 1
Management Algorithm
For nodules ≤20mm:
- Lobo-isthmectomy is the recommended surgical approach 2
- Active surveillance is a feasible alternative depending on patient age, comorbidities, and preferences 1
- Recent data shows 87.6% of nodules remain growth-free at 48 months under surveillance 3
For nodules >20mm or with concerning features:
- Surgery is generally recommended
- Consider total thyroidectomy if bilateral nodules present or nodule >4cm with suspicious features 2
Important Caveats
Frozen section biopsy is NOT recommended for Bethesda IV nodules during surgery because it cannot reliably distinguish benign from malignant follicular lesions 2. The diagnosis requires complete capsular examination on permanent sections.
Preoperative calcitonin assay is recommended to rule out medullary thyroid carcinoma before proceeding with surgery 1.
Risk Modifiers to Consider:
The presence of nuclear atypia within Bethesda IV significantly increases malignancy risk to 57.6% compared to 21.8% without nuclear atypia 4. This subclassification can help guide more aggressive management decisions.
Nodule size matters for surgical planning but not for avoiding surgery—malignancy risk remains significant at all sizes, with no safe cutoff to defer intervention 5.
Bottom Line
Bethesda IV is an indeterminate diagnosis requiring tissue diagnosis, not a cancer diagnosis. The majority (60-75%) will prove benign, but surgery is recommended because cytology cannot make this distinction preoperatively. For carefully selected patients with small nodules and no high-risk features, active surveillance with close monitoring is an acceptable alternative to immediate surgery 1, 3.